Google
XTLB — XTL BIOPHARMACEUTICALS LTD ADR (Healthcare >> Biotechnology)
XTLB FAQ
What is XTLB's ROE?
XTL BIOPHARMACEUTICALS LTD ADR reports a Return on Equity (ROE) of -32.51%.
What is XTLB's dividend yield?
XTL BIOPHARMACEUTICALS LTD ADR offers a dividend yield of 0.00%.
What is XTLB's Deepscope Quality Score?
Deepscope rates XTLB's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy XTLB?
Deepscope's AI Timing Score for XTLB is 2 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does XTLB belong to?
XTL BIOPHARMACEUTICALS LTD ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.06
Price
-0.17
(-7.62%)
Day Change
|
|
|---|
XTLB, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.06 |
| PBV / Sector |
0.88 / 4.63
GREAT
|
| Earning Per Share | -0.76 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.07 M
GREAT
|
| Average 1W Daily Value |
0.03 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:20 |
| Symbol | XTLB |
| Name | XTL BIOPHARMACEUTICALS LTD ADR |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 2.37 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4.80 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 26 Ben-Gurion St., Ramat Gan, Israel, 5112001
Phone: 972 3 611 6600
Website: https://www.xtlbio.com
Sector: Healthcare >> Biotechnology
Description: XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
